[Alpha Tau in Alpha Tau] Alpha Tau Medical receives Japanese marketing approval for Alpha DaRT® in unresectable locally advanced or locally recurrent head and neck cancer

JERUSALEM – February 24, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that Japan’s Ministry of Health, Labour and Welfare (“MHLW”) has granted regulatory (Shonin) marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.

Read more here.